| Literature DB >> 31310809 |
Shao-Bo Bai1, Dao-Zhou Liu1, Ying Cheng1, Han Cui1, Miao Liu1, Min-Xuan Cui1, Bang-le Zhang1, Qi-Bing Mei2, Si-Yuan Zhou3.
Abstract
Bone is one of the prone metastatic sites of lung cancer. Osteoclast plays an important role in bone resorption and the growth of bone metastases of lung cancer. In order to treat bone metastases of lung cancer, we reported a docetaxel (DTX)-loaded nanoparticle, DTX@AHP, which could target dually at osteoclasts and bone metastatic tumor cells. The in vitro drug release from DTX@AHP exhibited pH and redox responsive characteristics. DTX@AHP displayed high binding affinity with bone matrix. In addition, DTX@AHP significantly inhibited the differentiation of RAW264.7 into osteoclast and effectively inhibited the proliferation of osteoclasts and tumor cells in in-vitro 3D bone metastases model of lung cancer. DTX@AHP could accumulate in bone metastases sites in vivo. Consequently, DTX@AHP not only markedly inhibited the growth of bone metastases of lung cancer but also reduced osteolysis in tumor-bearing mice. DTX@AHP exhibited great potential in the treatment of bone metastases of lung cancer.Entities:
Keywords: Bone metastases of lung cancer; Docetaxel; Hyaluronic acid; Osteoclasts; PAMAM
Mesh:
Substances:
Year: 2019 PMID: 31310809 DOI: 10.1016/j.nano.2019.102054
Source DB: PubMed Journal: Nanomedicine ISSN: 1549-9634 Impact factor: 5.307